GERN +.01 to 2.10, I joined you with a few shares today. The risk/reward seems favorable ahead of next Thursday's Oncology Committee review meeting. I think a recommendation for FDA approval is likely. Of course, if they recommend against approval, the stock will get hit hard. Good luck.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.